Foundation One Liquid

Specimen Required

Blood/ Blocks

Fasting Required

Purpose of the Test

The FoundationOne Liquid test is used to help guide treatment decisions for patients with solid tumors, such as lung, breast, colon, and prostate cancer. The test can identify genetic alterations in the tumor cells that may be used to select targeted therapies, immunotherapies, or clinical trial options.

When this test is required

The test may be requested by a healthcare provider at various stages of cancer management, including diagnosis, treatment selection, and monitoring of disease progression and response to treatment.

What the Test Detects

The test examines the patient’s ctDNA for genetic alterations in over 300 cancer-related genes, including single nucleotide variants, small insertions or deletions, copy number alterations, and fusions/rearrangements.

Preparation for the Test

There is no specific test preparation needed for the FoundationOne Liquid test.

Sample Requirements

The test requires a blood sample from the patient.

Additional Notes

It is important to note that the FoundationOne Liquid test is just one tool that healthcare providers use to guide treatment decisions for solid tumors. Healthcare providers will typically use a combination of diagnostic tests and clinical evaluation to make a diagnosis and determine the appropriate treatment plan. Additionally, genetic testing can have limitations, and not all patients will have a genetic alteration that is targetable with currently available therapies.

Selected Tests